These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 27583545

  • 1. Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.
    Lo JH, Kwon EJ, Zhang AQ, Singhal P, Bhatia SN.
    Bioconjug Chem; 2016 Oct 19; 27(10):2323-2331. PubMed ID: 27583545
    [Abstract] [Full Text] [Related]

  • 2. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS, Yawata T, Honke K.
    Eur J Pharm Sci; 2014 Feb 14; 52():48-61. PubMed ID: 24178005
    [Abstract] [Full Text] [Related]

  • 3. Cationic Mucic Acid Polymer-Based siRNA Delivery Systems.
    Pan DW, Davis ME.
    Bioconjug Chem; 2015 Aug 19; 26(8):1791-803. PubMed ID: 26154102
    [Abstract] [Full Text] [Related]

  • 4. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
    Sakurai Y, Mizumura W, Ito K, Iwasaki K, Katoh T, Goto Y, Suga H, Harashima H.
    Mol Pharm; 2020 Apr 06; 17(4):1397-1404. PubMed ID: 32091909
    [Abstract] [Full Text] [Related]

  • 5. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer.
    Lo JH, Hao L, Muzumdar MD, Raghavan S, Kwon EJ, Pulver EM, Hsu F, Aguirre AJ, Wolpin BM, Fuchs CS, Hahn WC, Jacks T, Bhatia SN.
    Mol Cancer Ther; 2018 Nov 06; 17(11):2377-2388. PubMed ID: 30097486
    [Abstract] [Full Text] [Related]

  • 6. PEGylated cyclodextrins as novel siRNA nanosystems: correlations between polyethylene glycol length and nanoparticle stability.
    Godinho BM, Ogier JR, Quinlan A, Darcy R, Griffin BT, Cryan JF, O'Driscoll CM.
    Int J Pharm; 2014 Oct 01; 473(1-2):105-12. PubMed ID: 24992319
    [Abstract] [Full Text] [Related]

  • 7. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN.
    Acc Chem Res; 2012 Jul 17; 45(7):1163-71. PubMed ID: 22568781
    [Abstract] [Full Text] [Related]

  • 8. Combinatorial optimization of PEG architecture and hydrophobic content improves ternary siRNA polyplex stability, pharmacokinetics, and potency in vivo.
    Werfel TA, Jackson MA, Kavanaugh TE, Kirkbride KC, Miteva M, Giorgio TD, Duvall C.
    J Control Release; 2017 Jun 10; 255():12-26. PubMed ID: 28366646
    [Abstract] [Full Text] [Related]

  • 9. Peptide Spiders: Peptide-Polymer Conjugates to Traffic Nucleic Acids.
    Kwon EJ, Ko H, Bhatia SN.
    Mol Pharm; 2020 Sep 08; 17(9):3633-3642. PubMed ID: 32786959
    [Abstract] [Full Text] [Related]

  • 10. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer.
    Li SD, Huang L.
    Biochim Biophys Acta; 2009 Oct 08; 1788(10):2259-66. PubMed ID: 19595666
    [Abstract] [Full Text] [Related]

  • 11. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
    Guo J, Cheng WP, Gu J, Ding C, Qu X, Yang Z, O'Driscoll C.
    Eur J Pharm Sci; 2012 Apr 11; 45(5):521-32. PubMed ID: 22186295
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In Vivo Delivery of siRNAs Targeting EGFR and BRD4 Expression by Peptide-Modified Redox Responsive PEG-PEI Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
    Wan X, Sun R, Bao Y, Zhang C, Wu Y, Gong Y.
    Mol Pharm; 2021 Nov 01; 18(11):3990-3998. PubMed ID: 34591491
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.
    Yu MZ, Pang WH, Yang T, Wang JC, Wei L, Qiu C, Wu YF, Liu WZ, Wei W, Guo XY, Zhang Q.
    Eur J Pharm Sci; 2016 Sep 20; 92():39-48. PubMed ID: 27355138
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Post-PEGylation of siRNA Lipo-oligoamino Amide Polyplexes Using Tetra-glutamylated Folic Acid as Ligand for Receptor-Targeted Delivery.
    Müller K, Kessel E, Klein PM, Höhn M, Wagner E.
    Mol Pharm; 2016 Jul 05; 13(7):2332-45. PubMed ID: 27177200
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.
    Bartlett DW, Davis ME.
    Bioconjug Chem; 2007 Jul 05; 18(2):456-68. PubMed ID: 17326672
    [Abstract] [Full Text] [Related]

  • 20. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
    Chen S, Tam YY, Lin PJ, Leung AK, Tam YK, Cullis PR.
    J Control Release; 2014 Dec 28; 196():106-12. PubMed ID: 25285610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.